Quarry Thera, LLC
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Quarry Thera, LLC - overview
Established
2025
Location
New Haven, CT, US
Primary Industry
Biotechnology
About
Founded in 2025 by Mikael Dolsten, and based in Connecticut, US, Quarry Thera is a biotechnology company that provides proximity-induced therapeutics using molecular glue technology. In November 2025, Quarry Thera raised USD 32 million in series A funding from new investors Canaan Partners, F-Prime Capital, Lilly Ventures, and Yosemite Management. Quarry Thera is a biotechnology company focused on developing proximity-induced therapeutics using molecular glue technology. It utilizes proprietary DNA-encoded libraries, structure-guided drug design, and advanced medicinal chemistry to address proteins that were previously considered untreatable.
The company aims to address limitations of current therapies by creating small-molecule drugs that induce proximity between proteins to modulate their function.
Current Investors
Canaan Partners, Lilly Ventures, F-Prime Capital
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy
Verticals
HealthTech
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.